By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Veloxis Pharmaceuticals A/S 

Kogle Allé 4

  DK-2970  Hørsholm  Denmark
Phone: 457-033-3300 Fax:


SEARCH JOBS


Industry
Pharmaceutical






Company News
Veloxis Pharmaceuticals A/S (VELO) CEO to Step Down 12/11/2015 5:58:31 AM
Veloxis Pharmaceuticals A/S (VELO) Launches EnvarsusXR For Treatment Of Kidney Transplant Patients In U.S. 12/7/2015 7:35:27 AM
Veloxis Pharmaceuticals A/S (VELO) Establishes Sponsored Level 1 ADR Program In U.S. 10/14/2015 10:07:48 AM
Veloxis Pharmaceuticals A/S (VELO) Announces Publication Of Phase III-B STRATO Study Of Envarsus XR Demonstrating Reduction In Hand Tremors Compared To Twice-Daily Tacrolimus In Kidney Transplant Patients 9/21/2015 12:04:30 PM
Veloxis Pharmaceuticals A/S (VELO) Release: Envarsus XR Data To Be Presented At European Society Of Transplantation 9/10/2015 8:17:35 AM
Veloxis Pharmaceuticals A/S (VELO) Announces Financial Results For The First Six Months Of 2015 And Improves The Full Year Outlook 8/27/2015 6:31:57 AM
Veloxis Pharmaceuticals A/S (VELO) Envarsus XR Granted Orphan Drug Status By FDA For Kidney Transplant Rejection Prophylaxis 8/17/2015 9:35:44 AM
Veloxis Pharmaceuticals A/S (VELO) Announces U.S. FDA Approval of Envarsus XR For Treatment Of Kidney Transplant Patients 7/13/2015 6:35:57 AM
Veloxis Pharmaceuticals A/S (VELO) Release: Envarsus XR Demonstrates Differentiated Pharmacokinetic Profile Compared To Twice-Daily Prograf Or Once-Daily Astagraf XL In Stable Kidney Transplant Patients 6/24/2015 10:22:38 AM
U.S. District Court Rules In Veloxis Pharmaceuticals A/S (VELO) Litigation 6/15/2015 6:39:46 AM
123456789
//-->